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Abstract 
An 8-year old boy, affected by severe aplastic
anemia, developed  a probable pulmonary inva-
sive  aspergillosis  (IA)  early  after  a  second
unrelated allogeneic hematopoietic stem cell
transplant (HSCT). He was treated promptly
with  the  combination  of  liposomal  ampho-
tericin B and caspofungin. Despite the initial
stabilization, the patient deteriorated and the
antifungal therapy was switched to voricona-
zole  and  caspofungin.  The  patient  gradually
improved  and  was  discharged  home  on  day
+29 post-HSCT on oral voriconazole.  On day
+119,  a  sudden  episode  of  hemoptysis
occurred and a right superior lobectomy was
decided to remove the residual aspergilloma.
The patient is now alive and well more than 24
months  from  HSCT.  This  case  demonstrated
that antifungal combination therapy and sur-
gery  are  valid  options  to  cure  pulmonary  IA
even  in  patients  at  high-risk  and  severely
immunosuppressed.
Introduction
Despite  the  introduction  of  liposomal  for-
mulations of amphotericin B, broad spectrum
triazoles, and antifungals with a new mecha-
nism of action such as the echinocandins, the
mortality  from  IPA  remains  high  in  HSCT
patients.1 The  optimal  treatment  of  IPA  in
HSCT  patients  has  not  been  established.
Current recommendations do not distinguish
between  neutropenic  leukemic  and  HSCT
patients,  voriconazole  and  liposomal  ampho-
tericin B being mainly indicated as first-line
therapy.2 For  a  patient  refractory  to  initial
monotherapy,  switching  to  another  class  of
drug, i.e. caspofungin or another echinocan-
din, or the use of combination antifungal ther-
apy are both considered valid options although
there are limited data to guide this choice.3
We report a case of successful treatment of
disseminated IPA in a boy affected by severe
aplastic  anemia  who  underwent  a  second
unrelated  allogeneic  HSCT  for  primary  graft
failure. The successful outcome was obtained
by an intensive medical treatment (combina-
tion therapy with rotation of antifungals) and
delayed lung surgery.  
Case Report
An 8-year old latin-american boy was diag-
nosed  with  severe  aplastic  anemia  and  was
treated with 2 courses of immunosuppressive
therapy (IST) without obtaining a hematologi-
cal response. Fourteen months after diagnosis,
he underwent an unrelated cord blood trans-
plant that was HLA class I double mismatched.
Conditioning  was  based  on  fludarabine,
cyclophosphamide, and rabbit antilymphocyte
serum, and mini-total body irradiation, 1¥200
cGy/day.4 GVHD  prophylaxis  was  based  on
cyclosporin and a short course of methotrexate
(MTX). Unfortunately, the patient had a pri-
mary graft failure. A second allogeneic HSCT
was scheduled as soon as a HLA mismatched
unrelated donor was identified in the interna-
tional registries. The interval between the first
and  second  HSCT  was  5  months.  In  the  8
weeks before the second HSCT the patient was
treated  extensively  with  broad-spectrum
antibiotics  because  of  two  severe  infective
episodes: a sepsis by Staphylococcus warneri
and,  two  weeks  later,  a  sepsis  by  Stenotro  -
phomonas malthophilia resulting in bilateral
sinusitis  and  necrotizing  dental  abscess
extending to the hard palate. Given the persist-
ent aplasia the patient was started on prophy-
laxis  with  voriconazole  beginning  6  weeks
before the second HSCT.
Conditioning regimen for the second HSCT
was  fully  myeloablative  with  thiothepa,  2¥5
mg/kg/day  (day  -6),  cyclophosphamide,  4¥50
mg/kg/day, and rabbit antithymocyte globulin
(ATG  Fresenius-S,  Munich,  Germany),  4¥20
mg/kg/day, (from day - 5 to day - 2). As preven-
tion of post-transplant EBV-related lymphopro-
liferative disease, the patient received also rit-
uximab before stem cell infusion at the dose of
375 mg/m2. 
On day 0, the patient was infused with a
total number of nucleated cells of 7.8¥108/kg. 
The  twice-weekly  monitoring  of  serum
galactomannan  (GM)  showed  a  progressive
increase from 0.6 on day - 6 to 2.1 on day +1,
this latter day being characterized also by the
appearance of high fever (39°C), cough, and
bronchial  breath  sound  to  the  left  lung.  An
urgent CT scan of the lungs showed 3 radio-
logical lesions with ground glass ring consis-
tent with probable IPA involving the left supe-
rior lobe, the left inferior lobe, and right infe-
rior lobe. A combination therapy with liposo-
mal  amphotericin  B  (Ambisome® Gilead,
Milan,  Italy),  3  mg/kg/day,  and  caspofungin,
1¥70 mg/m2 followed by 1¥50 mg/m2/day, was
started. In the following week both fever and
patient  clinical  findings  remained  stable
whereas the serum GM cut-off index contin-
ued  to  rise  to  4.5.  Blood  cultures  and  viral
search (cytomegalovirus, adenovirus, respira-
tory syncitial virus, Epstein-Barr virus, Human
Herpes virus 6) remained always negative. On
day + 11, the patient deteriorated with higher
fever, polypnea, hypoxemia, important pleural
pain  to  left  hemithorax.  The  lung  CT  scan
showed a further extension of lung involve-
ment with parenchymal consolidation extend-
ing to almost all the left lung and pleural effu-
sion  (Figure  1).  GM  cut-off  index  further
increased  to  8.  The  antifungal  combination
therapy  was  switched  to  voriconazole  and
caspofungin,  and  G-CSF  was  started  (day
+13).  The patient gradually improved and the
fever  disappeared  as  well  as  the  oxygen
dependence.  The  neuthrophil  engraftment
was on day + 18. Caspofungin was suspended
and the patient was discharged home on day +
29  on  oral  voriconazole  with  a  GM  cut-off
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index lower but still abnormal, 2.09. In the fol-
lowing months, the clinical conditions contin-
ued to improve as demonstrated by a further
lung CT scan on day  + 60  whereas the GM
cut-off  index  persisted  abnormal,  though
decreasing: 2.6-2.9 in the second month, and
1.07  in  the  third  month.  On  day  +119,  the
patient  presented  with  a  sudden  episode  of
hemoptysis. The lung CT scan showed persist-
ence of a consolidation area at the right supe-
rior  lobe  with  involvement  of  the  bronchi
(between the dorsal portion of the left superi-
or lobar bronchus and the anterior portion of
the left inferior lobar broncus). It was decided
to perform a left superior lobectomy to prevent
the risk of sudden fatal hemorrhages. The his-
tological  examination  was  consistent  with
aspergilloma (Figure 2). The GM cut-off level
became  persistently  negative  after  surgery.
The patient continued on voriconazole as sec-
ondary prophylaxis. Repeated lung CT scans
and GM serum determinations confirmed the
complete resolution of pulmonary aspergillo-
sis. At 26 month after HSCT, the patient is
alive  and  well,  with  full  donor  engraftment,
and enjoys a normal life.  
Discussion
The introduction of new drugs or new formu-
lations has contributed to improve the progno-
sis of IPA after chemotherapy whereas the suc-
cess rate in HSCT patients still remains unsat-
isfactory: the favourable response is 32.4% with
voriconazole and 47% with Ambisome®, and the
corresponding  figures  as  rescue  therapy  are
14%  for  caspofungin,  and  38%  for  voricona-
zole.5-8
The  combination  of  antifungal  drugs,  in
order to obtain a synergistic effect by acting on
different targets of the fungal cell components,
has been proposed as an alternative to treat-
ment with a single antifungal agent. The recent
updated guidelines of the European Conference
on  Infectious  Complications  in  Leukemic
patients  stated  that  combination  antifungal
therapy is optional in patients who need rescue
treatment.2
Our patient presented with many factors that
may  have  impacted  negatively  on  survival,
because  he  received  a  second  myeloablative
HSCT  having  been  immunodepressed  and
severely  neutropenic  for  several  months.
Moreover, he was treated with broad spectrum
antibiotics  for  2  episodes  of  bacterial  sepsis,
and the invasive aspergillosis developed despite
prophylaxis with voriconazole. For all these rea-
sons,  we  decided  to  maximize  the  treatment
using antifungal combination therapy from the
beginning. The use of Ambisome and caspofun-
gin  initially  obtained  a  stabilization  of  the
patient clinical parameters but the combination
was changed to voriconazole and caspofungin
after  a  subsequent  clinical  and  radiological
worsening of the patient. This fact does not cer-
tainly mean the failure of antifungal therapy
because the clinical and radiological worsening
is  sometimes  described  concurrently  with
patient myeloid recovery or neutrophil engraft-
ment, due to the so called inflammatory sys-
temic response. Although the data are limited,
we opted to switch to a salvage therapy with the
combination  of  voricozole  and  caspofungin
because it was associated to a reduced mortali-
ty in patients with IA after allogeneic HSCT.9
Caillot et al. showed that aggressive surgery
has a role in preventing fatalities due to mas-
sive hemorrhages in patients with invasive pul-
monary aspergillosis and hemoptysis.10 Despite
that, its role in the treatment of lung aspegillo-
sis is still considered optional due to the fear of
post-surgical morbidity, especially after HSCT.2
In this patient, the surgery contributed to speed
the  complete  eradication  of  residual  lung
lesions as demonstrated by the persistent nega-
tivity of GM and the absence of recurrent pul-
monary  fungal  infection  in  the  following
months. 
In  conclusion,  this  case  showed  that  both
antifungal combination therapy and surgery are
a valid option to treat an IPA occurring in the
early phase post-HSCT in a pediatric patient.
We  recognize  that  more  data  are  needed  to
assess the role of combination antifungal ther-
apy and of surgery in this setting but the com-
plexity  and  poor  prognostic  profile  of  these
patients may pose problems in the design of a
prospective study.  
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Case Report
Figure 1. Diffuse parenchyma involvement
with consolidation to almost all left lung
and pleural effusion.
Figure 2. Septatae hyphae consistent with
Aspergillus infection  in  the  granuloma
removed surgically. 